Form 8-K - Current report:
SEC Accession No. 0001213900-26-049347
Filing Date
2026-04-29
Accepted
2026-04-29 16:41:33
Documents
13
Period of Report
2026-04-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0288202-8k_citius.htm   iXBRL 8-K 33370
2 PRESS RELEASE, DATED APRIL 29, 2026 ea028820201ex99-1.htm EX-99.1 35672
3 GRAPHIC ea028820201_ex99-1img1.jpg GRAPHIC 16342
  Complete submission text file 0001213900-26-049347.txt   267808

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctor-20260429.xsd EX-101.SCH 3017
5 XBRL LABEL FILE ctor-20260429_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE ctor-20260429_pre.xml EX-101.PRE 22360
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0288202-8k_citius_htm.xml XML 3294
Mailing Address 11 COMMERCE DRIVE FIRST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6677
CITIUS ONCOLOGY, INC. (Filer) CIK: 0001851484 (see all company filings)

EIN.: 994362660 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-41534 | Film No.: 26917107
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)